Pancreatitis Incidence in the Exenatide BID, Exenatide QW, and Exenatide QW Suspension Development Programs: Pooled Analysis of 35 Clinical Trials
ConclusionIn this pooled analysis of 10,058 patients among studies comparing exenatide with other glucose-lowering medications or placebo, pancreatitis was rare. The EAIRs of pancreatitis were low and similar between exenatide and non-exenatide treatment groups. No evidence of an association between exenatide and pancreatitis was observed.FundingBristol-Myers Squibb and AstraZeneca.Plain Language SummaryPlain language summary available for this article.
Source: Diabetes Therapy - Category: Endocrinology Source Type: research
More News: AstraZeneca | Byetta | Clinical Trials | Databases & Libraries | Diabetes | Diabetes Mellitus | Diabetes Type 2 | Endocrinology | Incretin Therapy | Pancreatitis | Study